Company Filing History:
Years Active: 2022-2025
Title: Boi Bryant Quach: Innovator in Cancer Immunotherapy
Introduction
Boi Bryant Quach is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of cancer immunotherapy through his innovative research and patented technologies. With a total of 2 patents, Quach is recognized for his work in identifying antigen-specific T cells, which plays a crucial role in advancing cancer treatment.
Latest Patents
Quach's latest patents focus on compositions and methods for the identification of antigen-specific T cells. These patents disclose antigenic peptide-MHC complexes, referred to as comPACT polypeptides and comPACT polynucleotides. The methods outlined in these patents include the production of such complexes and the creation of libraries of comPACT polynucleotides and polypeptides. These innovations are exemplary in capturing cancer neoepitope-reactive T cells with high accuracy. Additionally, the patents provide dual particle detection approaches for detecting neoantigen-specific T cells with improved sensitivity and specificity. They also include signal-to-noise ratio analysis of isolated T cells for enhanced detection of neoantigen-specific T cells.
Career Highlights
Throughout his career, Quach has worked with various companies, including Adoc Ssf, LLC and Pact Pharma, Inc. His experience in these organizations has allowed him to further develop his expertise in cancer immunotherapy and contribute to groundbreaking research in the field.
Collaborations
Quach has collaborated with notable colleagues, including Songming Peng and Duo An. These partnerships have facilitated the exchange of ideas and advancements in their shared research interests.
Conclusion
Boi Bryant Quach is a distinguished inventor whose work in cancer immunotherapy has led to significant advancements in the identification of antigen-specific T cells. His innovative patents and collaborations highlight his commitment to improving cancer treatment methodologies.